Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

Submission seeks approval of momelotinib for the treatment of myelofibrosis SAN MATEO, Calif.--(BUSINESS WIRE) June 17, 2022 -- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news